• Explore /
  • Poster
  • / Preclinical antitumor activity of nanoliposomal irinotecan (Nal-IRI, MM-398) and utilization as a foundation of front-line pancreatic cancer regimens.

Preclinical antitumor activity of nanoliposomal irinotecan (Nal-IRI, MM-398) and utilization as a foundation of front-line pancreatic cancer regimens.

Abstract Poster

Authors

null

Daniel F. Gaddy

Merrimack Pharmaceuticals, Inc., Cambridge, MA

Daniel F. Gaddy , Helen Lee , Nancy Paz , Shannon C. Leonard , Ashish Kalra , Ninfa L. Straubinger , Robert M Straubinger , Bryan M. Gillard , Michael T. Moser , Barbara A. Foster , Daryl C. Drummond , Stephan G. Klinz , Bart Hendriks , Jonathan B. Fitzgerald

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Translational Research

Citation

J Clin Oncol 35, 2017 (suppl 4S; abstract 336)

DOI

10.1200/JCO.2017.35.4_suppl.336

Abstract #

336

Poster Bd #

F6

Abstract Disclosures

Similar Posters

First Author: Benedikt Westphalen

First Author: Zev A. Wainberg

First Author: Ben M. Chue

First Author: Li-Tzong Chen